s-1360 go on or failed?
Nov 2, 2003
s-1360 a winner or failed?
Integrase Inhibitor: S-1360 S-1360 is a diketo acid being developed by Shinogi Pharmaceuticals and GlaxoSmithKline. Preliminary data from early preclinical and clinical studies were reported at the 2002 Retrovirus conference and at the XIV International AIDS Conference in Barcelona. According to in vitro data reported at the Seattle meeting, S-1360 is synergistic with all of the available antiretrovirals and has potency that is on a par with lamivudine. In animal models, S-1360 was found to be 70 to 80 bio-available and had a half-life ranging from one to two hours. As for clinical data, 18 HIV-negative study volunteers received single doses of S-1360. In all 18 people, the plasma half-life ranged from 7.7 to 16 hours, meaning that once-daily dosing is possible. Phase I and II studies of S-1360, in HIV-infected people, are under way.
Response from Dr. Pierone
Unfortunately it failed and is no longer being developed.
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Itchy Rash During Window Period
- Fever After Vaginal Sex Worried I Have HIV
- Itchy Testicles After Touching A Bloody Scab Sign Of HIV AIDS
- Rectal Bleeding After Vaginal Sex Without Condom Does It Mean I Have HIV
- Sore On Tongue After Swallowing Precum What Are The Chances Of HIV
- Tingling Lips After Kissing Cut On Lip Worried I Have HIV
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.